Editorial
Copyright ©2011 Baishideng Publishing Group Co.
World J Hepatol. May 27, 2011; 3(5): 99-107
Published online May 27, 2011. doi: 10.4254/wjh.v3.i5.99
Table 1 Effects of anti-diabetic agents in patients with chronic liver disease
Anti-diabetic agentSubjectsOutcomeReference
Exogenous insulin or sulphonylureaPatients with liver cirrhosis or HCCIncreased HCC risk[100]
Exogenous insulin or sulphonylureaPatients with chronic hepatitis CIncreased HCC risk[101]
Exogenous insulinChronic viral hepatitis patients who had undergone curative resection for HCCIncreased risk of HCC recurrence[102]
MetforminTreatment-naïve female patients with HCV genotype 1-related chronic hepatitis and insulin resistanceIncreased SVR rate[16]
MetforminPatients diabetes mellitus and liver cirrhosis or HCCDecreased HCC risk[101]
MetforminPatients with liver cirrhosis or HCCDecreased HCC risk[112]
PioglitazoneChronic hepatitis C patients who had previously failed to respond to antiviral therapyNo increase in EVR rate[115]
PioglitazoneTreatment-naïve chronic hepatitis C patients with insulin resistanceIncreased SVR rate[116]